Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Regenerative Medical Technology Group Inc. reported revenue of $5M, up 24.2% year over year. Operating margin was -17.0% and net margin -153.2%, on a free-cash-flow margin of -25.7% with capital expenditure at 11.8% of revenue. Every figure is computed directly from RMTG's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $5M | -17.0% | -153.2% |
| FY2024 | $4M | 2.0% | -135.4% |
| FY2023 | $2M | -29.7% | -407.2% |
| FY2022 | $2M | n/a | -359.9% |
| FY2021 | $0M | n/a | -2942.4% |
How does RMTG compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAP · ACI · AEO · AIXN · AKA · AMZN
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.